- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
UCB, Inc. v. Annora Pharma Priv. Ltd.
Briviact® (brivaracetam)
August 16, 2023
Case Name: UCB, Inc. v. Annora Pharma Priv. Ltd., Civ. No. 20-987-CFC, 2023 WL 5274566 (D. Del. Aug. 16, 2023) (Connolly, J.)
Drug Product and Patent(s)-in-Suit: Briviact® (brivaracetam); U.S. Patent No. 6,911,461 (“the ’461 patent”)
Nature of the Case and Issue(s) Presented: UCB sued Annora, Apotex, and MSN, alleging that their ANDAs infringe one claim of one patent. The asserted claim described the compound brivaracetam, used to treat partial-onset seizures in epilepsy patients. Defendants did not dispute that they infringe the asserted claim; they mounted a lone obviousness defense. After a bench trial, the court issued findings of facts and conclusions of law finding the asserted claim infringed and not invalid.
Why UCB Prevailed: The court’s analysis began with a simple premise: “[i]t is undisputed that brivaracetam is an analogue of the compound levetiracetam, a predecessor compound patented by UCB in 1987 and approved by the FDA in 1999 for the treatment of epilepsy-related seizures.” The compounds share the same chemical formula in all but one respect: brivaracetam has a propyl group at the 4-position of the pyrrolidine ring. So went Defendants’ obviousness argument: it would have been obvious to a skilled artisan to select levetiracetam as a lead compound from which to develop new anti-seizure drugs and to modify levetiracetam by increasing its lipophilicity with the addition of a propyl group to the 4-position of its pyrrolidine ring.
At trial, UCB argued that a skilled artisan would not have started with levetiracetam when looking to develop a new anti-seizure drug. But despite its trial argument, post-trial, UCB stipulated that it would not challenge Defendants’ assertion that a skilled aritsan would have chosen levetiracetam as a lead compound “for further development efforts.” (The court seemed puzzled by the concession.) As a result of UCB’s concession, the court decided only one issue: whether it would have been obvious to modify levetiracetam by increasing its lipophilicity with the addition of a propyl group to the 4‑position of its pyrrolidine ring.
Ultimately, the court determined that Defendants did not carry their burden in proving a reasonable expectation of success in modifying a compound to increase lipophilicity to increase antiepileptic activity. As part of that conclusion, the court found that a skilled artisan would not have been motivated to improve levetiracetam’s brain uptake, because levetiracetam was already a successful central nervous system drug and increasing brain uptake would risk increasing its side effects. Further, a skilled artisan would not have thought to increase levetiracetam’s lipophilicity. And even if a skilled artisan were motivated to focus on lipophilicity, in view of the prior art, Defendants could not show that a skilled artisan would have been motivated to modify levetiracetam at the 4-position of the pyrrolidine ring.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.